Chartered Patent Attorney
European Patent Attorney
Arnie has an Honours Degree and a Ph.D. in Chemistry from the University of Cambridge.
Arnie originally joined Gill Jennings & Every in 1997, where he qualified, before moving to another firm of patent attorneys for three years. He then returned to GJE in 2007, becoming a partner of the firm in 2008. He qualified as both a Chartered and European Patent Attorney in 2002.
Arnie works in the fields of pharmaceutical, medicinal, industrial, food and organic chemistry, with particular expertise in small molecule pharmaceutical chemistry, secondary formulation of pharmaceutical products and industrial formulation chemistry. Arnie’s principal clients have included The Procter & Gamble Company, Honeywell International, Sosei R&D Ltd., Proximagen, Mylan, Teva Pharmaceutical Industries, IAMS, Idemitsu Kosan, AstraZeneca, Pozen, Neutec and Duramed.
He specialises in contentious inter partes proceedings before the European Patent Office and has considerable experience in both oppositions and appeals, having been involved in over 150 oppositions. He currently attends between 20 and 30 hearings per year at the EPO. Arnie applies the experience gained from these contentious proceedings to his drafting and prosecution practice, so as to future-proof patent applications against subsequent opposition or litigation. He regularly deals with multi-party proceedings and has experience in handling and supporting contentious cases involving parallel proceedings in multiple jurisdictions.
Arnie has been involved in numerous high profile projects and disputes in the pharmaceutical field, including those involving omeprazole (Prilosec®), glycopyrrolate (Seebri®), tiotropium (Spiriva®), sumatriptan/naproxen sodium (Treximet®), formoterol/budesonide (Symbicort®), quetiapine (Seroquel®), glatiramer (Copaxone®), ritonavir (Norvir®), lopinavir (Kaletra®), naproxen/esomeprazole magnesium (VIMOVO®), rivastigmine (Exelon®), travoprost (Travatan®), fluvastatin (Lescol®), exenatide (Byetta®), sevelamer (Renagel®), olanzapine (Zyprexa®), mycophenolate (Mofetil®), oxiplatin (Eloxatin®) and entecavir (Baraclude®). In the industrial chemistry field, recent high profile cases he has been involved in include appeals T 860/12, T1799/12, T0453/08 and T1643/12.
His success statistics for final, non-appealable decisions before the EPO Opposition and Appeal Boards are significantly better compared to the average of the current UK Legal 500 Top Tier Firms, all European Firms, all UK Firms and all German Firms.